Joel Greenblatt fit · Magic Formula — ROIC alto + EV/EBIT barato
Is Acadia Pharmaceuticals Inc. (ACAD) a Joel Greenblatt Stock?
Partial match — either cheap or high-quality, but not both.
62/100
CSeñales mixtas
2/5 criterios cumplidos
Los criterios de Joel Greenblatt, aplicados a ACAD
EBIT/EV yield ≥ 10%
clave3.6%
ROIC ≥ 25%
clave25.2%
EV/EBIT ≤ 12
27.7x
Gross margin ≥ 30%
91.9%
Cómo se valora ACAD en otras estrategias
Datos financieros en vivo
Cap. mercado
$4.65B
PER (TTM)
19.0x
ROIC (TTM)
25.22%
Margen bruto
91.92%
Preguntas frecuentes
What is ACAD's Joel Greenblatt fit score?
ACAD scores 62/100 on our Joel Greenblatt fit engine — grade C. Partial match — either cheap or high-quality, but not both.
Does Joel Greenblatt actually own ACAD?
Our score is computed from financial fundamentals against Joel Greenblatt's published criteria. We don't claim that Joel Greenblatt personally owns or recommends ACAD.
How often is this score updated?
ACAD's Joel Greenblatt fit score is recomputed daily from the latest TTM financials.
Herramienta educativa, no es asesoramiento financiero. Las puntuaciones se calculan a partir de datos financieros públicos contra los criterios publicados de cada estrategia de inversión. No afirmamos que Joel Greenblatt posea o recomiende ACAD personalmente.